• Synribo


Facts of Synribo (omacetaxine mepesuccinate ) ?

  • Medicine Name: Synribo
  • Generic Name: omacetaxine mepesuccinate
  • Approval Date: Sept. 4, 2012
  • Company Name: Teva Pharmaceuticals USA, Inc.
  • Available as (Form & Strength): Single-use vial containing 3.5 mg of om acetaxine mepesuccinate as a lyophilized powder.

Product Description

What are the indications and usage?

SYNRIBO for Injection is indicated for the treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKI). This indication is based upon response rate. There are no trials verifying an improvement in disease-related symptoms or increased survival with SYNRIBO.

How supplied/storage and handling ?

SYNRIBO (omacetaxine mepesuccinate) for Injection is supplied in 8 mL clear glass single- use vial in individual cartons. Each vial contains 3.5 mg of SYNRIBO (omacetaxine mepesuccinate) for Injection (NDC 63 459-177-14).

Store at 20 o C to 25ºC (68 o C to 77ºF); excursions permitted from 15ºC to 30ºC (59ºF to 86ºF). Until use, keep product in carton to protect from light.


There are no reviews yet.

Be the first to review “Synribo”